Literature DB >> 24676361

FRZB knockdown upregulates β-catenin activity and enhances cell aggressiveness in gastric cancer.

Shuai Qin1, Zhuo Zhang2, Jianfang Li3, Lu Zang2.   

Abstract

Studies have shown that FRZB correlates with gastric tumorigenicity and may play role in regulating the Wnt/β‑catenin signaling pathway. In the present study, we investigated the correlation between FRZB and the Wnt/β‑catenin signaling pathway using gastric cancer tissues and an FRZB‑knockdown gastric cancer cell line model. The protein levels of FRZB and β‑catenin were examined using immunohistochemical staining. FRZB-specific shRNAs were used to generate FRZB‑knockdown MKN45 gastric cancer cells. Cell proliferation assay, suspending culture and Annexin V/PI double staining analysis were used to investigate the role of FRZB knockdown in cell growth. In vitro migration/invasion assays were performed. The expression of Wnt/β‑catenin downstream targets was analyzed by RT-PCR. FRZB mRNA levels showed negative correlation with β‑catenin levels in paired non-tumor and tumor tissues. FRZB protein levels were negatively correlated with β‑catenin levels analyzed by IHC staining. Furthermore, high FRZB protein levels were correlated with membrane localization of β‑catenin. FRZB knockdown increased gastric cancer cell growth in monolayer and soft agar culture; it increased cell aggregates in suspending culture and rendered less apoptosis which indicated increased anti-anoikis growth. FRZB knockdown increased cell migration and invasion and increased the expression of Wnt/β‑catenin downstream targets such as MMP7 and cyclin D1. Our studies revealed that FRZB levels were correlated with β‑catenin subcellular localization. Knockdown of FRZB in gastric cancer cells increased cell growth and migration/invasion which was also accompanied by activation of Wnt/β‑catenin downstream targets. FRZB knockdown may upregulate the Wnt/β‑catenin pathway and promote aggressiveness in gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24676361     DOI: 10.3892/or.2014.3109

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  FRZB up-regulated in hepatocellular carcinoma bone metastasis.

Authors:  Jia Huang; Wenhao Hu; Xiangjin Lin; Xuanwei Wang; Ketao Jin
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.

Authors:  Lu Wang; Zibo Zhao; Patrick A Ozark; Damiano Fantini; Stacy A Marshall; Emily J Rendleman; Kira A Cozzolino; Nundia Louis; Xingyao He; Marc A Morgan; Yoh-Hei Takahashi; Clayton K Collings; Edwin R Smith; Panagiotis Ntziachristos; Jeffrey N Savas; Lihua Zou; Rintaro Hashizume; Joshua J Meeks; Ali Shilatifard
Journal:  Nat Med       Date:  2018-05-21       Impact factor: 53.440

3.  FRZB up-regulation is correlated with hepatic metastasis and poor prognosis in colon carcinoma patients with hepatic metastasis.

Authors:  Yanping Shen; Fang Zhang; Huanrong Lan; Ke Chen; Qi Zhang; Guoming Xie; Lisong Teng; Ketao Jin
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

4.  Melatonin induces apoptosis and cell cycle arrest in cervical cancer cells via inhibition of NF-κB pathway.

Authors:  Tarun Minocha; Megha Das; Vipin Rai; Sumit Singh Verma; Nikee Awasthee; Subash Chandra Gupta; Chandana Haldar; Sanjeev Kumar Yadav
Journal:  Inflammopharmacology       Date:  2022-04-17       Impact factor: 5.093

5.  Integrated Analysis Identifies Molecular Signatures and Specific Prognostic Factors for Different Gastric Cancer Subtypes.

Authors:  Li Min; Yu Zhao; Shengtao Zhu; Xintao Qiu; Rui Cheng; Jie Xing; Linlin Shao; Shuilong Guo; Shutian Zhang
Journal:  Transl Oncol       Date:  2016-12-22       Impact factor: 4.243

6.  Increased expression of the thyroid hormone nuclear receptor TRα1 characterizes intestinal tumors with high Wnt activity.

Authors:  Joel Uchuya-Castillo; Nicolas Aznar; Carla Frau; Pierre Martinez; Clementine Le Nevé; Laetitia Marisa; Luiz O F Penalva; Pierre Laurent-Puig; Alain Puisieux; Jean-Yves Scoazec; Jacques Samarut; Stephane Ansieau; Michelina Plateroti
Journal:  Oncotarget       Date:  2018-07-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.